Actively Recruiting
Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
Led by Suping ZHANG · Updated on 2024-04-01
60
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab. Anti-treatment was followed by DLI, and the second course was performed 1-2 months after DLI. Patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment. (MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg). Objective To observe and analyze the efficacy and side effects of Blinatumomab followed by donor lymphocyte infusion in patients with relapsed acute B lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation in our hospital.
CONDITIONS
Official Title
Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 years old or younger
- Stable vital signs
- No severe infection
- No grade II-IV graft-versus-host disease
- No organ failure
You will not qualify if you...
- Age over 65 years old
- Unstable vital signs
- Severe infection
- Grade II-IV graft-versus-host disease
- Heart, liver, kidney, or other organ failure
- Central nervous system leukemia
- Allergy to medications used in treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Zhengzhou University
Zhenzhou, Henan, China, 450000
Actively Recruiting
Research Team
S
Suping ZHANG
CONTACT
Z
Zhilei BIAN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here